Loading, Please Wait...
SAN FRANCISCO, May 07, 2019 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended March 31, 2019.
First Quarter 2019 Highlights
“We are off to a great start in 2019 with strong first quarter revenue growth and continued gross margin improvement,” said Kevin King, CEO. “Our business continues to strengthen on all fronts. Zio’s proven clinical superiority, the completeness of our service, combined with the broad strength of our sales and support organization continues to create meaningful value for our customers both large and small. I am confident that the opportunities arising from the expansion of our market through our clinical research efforts along with the expected full commercial launch of ZioAT in the second half of this year position us for continued success in the near and long-term.”
First Quarter Financial Results
Revenue for the three months ended March 31, 2019 increased 54% to $47.2 million, from $30.6 million during the same period in 2018. The increase was primarily due to increased salesforce productivity, expansion into new accounts, improved penetration of existing accounts, and a continued shift to higher priced contracted units.
Gross profit for the first quarter of 2019 was $35.5 million, or 75.2% gross margin, up from $22.0 million, or gross margin of 71.8%, during the same period in 2018.
Operating expenses for the first quarter of 2019 were $43.5 million, compared to $32.6 million for the same period in 2018. The increase in operating expenses was driven by salesforce expansion, organizational support for our network sales strategy, expansion of R&D activities, bad debt expense associated with higher sales volumes and ongoing stock compensation expense.
Net loss for the first quarter of 2019 was $8.0 million, or a loss of $0.33 per share, compared with net loss of $11.1 million, or a loss of $0.47 per share, for the same period in 2018.
Updated Guidance for Full Year 2019
iRhythm projects revenue for the full year 2019 to range from $206 million to $211 million, which represents 40% to 44% growth over the company’s prior year. Gross margins for the full year 2019 are expected to range from 75% to 76% and operating expenses for the full year 2019 to be between $193 million to $199 million including $28 million to $30 million for research and development and $165 million to $169 million for SG&A. This compares to previous revenue guidance of $201 million to $206 million; operating expenses of $191 million to $197 million and SG&A of $163 million to $167 million.
The company expects sales headcount to reach approximately 130 to 140 by year end 2019.
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for International callers, and referencing Conference ID: 6451448 or from the webcast on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, ability to penetrate the market and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission on the Form 10-K on March 4, 2019. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.
Investor Relations Contact:
Lynn Pieper Lewis or Leigh Salvo
IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
|March 31,||December 31,|
|Cash and cash equivalents||$||28,235||$||20,023|
|Accounts receivable, net||28,252||21,977|
|Prepaid expenses and other current assets||3,810||4,100|
|Total current assets||93,308||106,482|
|Operating lease right-of-use asset||9,232||-|
|Property and equipment, net||10,208||9,158|
|Liabilities and Stockholders’ Equity|
|Accrued interest, current portion||129||139|
|Operating lease liabilities, current portion||5,052||-|
|Total current liabilities||28,549||30,236|
|Deferred rent, noncurrent portion||-||153|
|Operating lease liabilities, noncurrent portion||3,990||-|
|Commitments and contingencies|
|Additional paid-in capital||261,231||257,955|
|Accumulated other comprehensive loss||2||(41||)|
|Total stockholders’ equity||49,723||54,422|
|Total liabilities and stockholders’ equity||$||117,184||$||119,710|
IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
|Three Months Ended March 31,|
|Cost of revenue||11,730||8,611|
|Research and development||6,756||4,019|
|Selling, general and administrative||36,705||28,577|
|Total operating expenses||43,461||32,596|
|Loss from operations||(7,977||)||(10,642||)|
|Loss before income taxes||(8,007||)||(11,117||)|
|Income tax provision||12||-|
|Net loss per common share, basic and diluted||$||(0.33||)||$||(0.47||)|
|Weighted-average shares used to compute net loss per common share, basic and diluted||24,474,308||23,479,955|